GSK starts work on $153m anti inflammatories and gastro drug plant in India

By Gareth Macdonald

- Last updated on GMT

GSK plant in India will make 8 billion tablets a year when operational in 2017
GSK plant in India will make 8 billion tablets a year when operational in 2017

Related tags Gsk

GSK has started work on an anti-inflammatory and gastrointestinal drug production plant in Vemgal, India which will create 300 manufacturing jobs.

The manufacturing facility will be located at a 50 acre site in the Vemagal industrial area, Kolar district in Karnataka State in southern India.

Anna Carruth, a spokeswoman for the UK-headquartered pharmaceutical confirmed that construction has begun, telling in-Pharmatechnologist.com “today was the laying of the first stone in the build.”

She said that: “The factory will make more than 8 billion tablets and 1 billion capsules a year in the areas of gastroenterology and anti-inflammatory medicines for the Indian market​” adding that the site will employ “in the region of 300, once fully operational​.”

Construction will cost around £100m ($153m) according to Carruth, who said: “The facility is part of GSK’s continued commitment to India, ensuring increased access to GSK medicines for people in the country​.” The site is expected to be operational in 2017.

99 year lease

GSK was granted rights to use the 50 acre lot by the Karnataka regional government last year. In 2013, CEO GSK Andrew Witty​ said the firm would increase its presence in India.

The UK drugmaker has not acquired the land. Instead it has been granted a 99-year lease by the regional Government, which opted to stop selling industrial plots to manufacturers last year.

Prior to that decision companies could either buy land outright or lease it for a maximum of 30 years.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us

Products

View more

Webinars